Rainer Krahl

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Dietger W. Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke et autres

A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study …

lt, de, jp (code pays fourni par la source)

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Thomas Heinicke, Rainer Krahl, Christoph A. Kahl, Michael A. Cross et autres

de, at, lt, jp (code pays fourni par la source)

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Thomas Heinicke, Rainer Krahl, Christoph A. Kahl, Michael A. Cross et autres

Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881), 74.2% reached complete remission (CR) 1 after induction(s) …

de, at, lt, jp (code pays fourni par la source)

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl et autres

Introduction The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).Method After in vitro testing and a phase I study (n = 20), 59 patients were randomized in the IM/HU and 29 in the …

de, us, lt, jp (code pays fourni par la source)

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Dietger W. Niederwieser, Rainer Krahl, Christoph A. Kahl, Hans‐Heinrich Wolf et autres

Introduction: Outcome of patients (pts) with refractory AML or following relapse is considered dismal and usually reported as refractory/relapsed. Here we analyzed long term outcome of refractory and relapsing pts separately over a 10 year (y) period from two prospective, non-age-limited, adult …

de, at, gb (code pays fourni par la source)

Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)

Nadia Jaekel, Karolin Hubert, Rainer Krahl, Mathias Haenel et autres

Abstract Age >60 years (y) is independently associated with poorer outcomes in AML. An increasing incidence of s-AML and t-AML as well as age-related genetic abnormalities increase the likelihood of resistance to treatment. After intensive chemotherapy (IC), complete remission (CR/CRi) rates of …

de, gb (code pays fourni par la source)

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)

Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt, Marc Andrea et autres

de (code pays fourni par la source)

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

Dietger W. Niederwieser, Verena Sophia Hoffmann, Markus Pfirrmann, Haifa Kathrin Al‐Ali et autres

Abstract Despite recent advances, treatment of elderly patients with AML remains a challenge because of adverse disease biology, comorbidities and therapy related toxicities. The balance between effectivity and toxicity of treatment strategies play a key role. Since comparative studies are lacking, a …

de, at (code pays fourni par la source)

Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk: Report from the AML 2004 of the East German Study Group (OSHO).

Dietger W. Niederwieser, Haifa Kathrin Al‐Ali, Rainer Krahl, Christoph A. Kahl et autres

e18501 Background: HSCT has been reported to be a treatment option for elderly patients with AML. Here we analyze the outcome of CT compared to HSCT in elderly AML patients according to genetic risk groups defined by the European Leukemia Net. Methods: …

de (code pays fourni par la source)

Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

Christian Niederwieser, Sven Starke, Laura E. Fischer, Rainer Krahl et autres

us, de (code pays fourni par la source)

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

Dietger W. Niederwieser, Verena Sophia Hoffmann, Utz O. Krug, Rainer Krahl et autres

Abstract Background The German AML Intergroup conducted two randomized studies in younger (<60 years) and elderly (≥60 years) patients in which the study arms were compared to a common standard arm. Here, we compared the two studies in younger and elderly patients …

de, nz (code pays fourni par la source)

The Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) and Treatment with Ruxolitinib on Survival in Patients with Myelofibrosis

Nadja Jaekel, Song‐Yau Wang, Rainer Krahl, Karolin Hubert et autres

Abstract Allogeneic HCT is curative in myelofibrosis (MF) with a survival (OS) advantage compared to non-JAK-inhibitor treatments in patients (pts) with Int-2/high-risk DIPSS (Kroeger et al, Blood 2015). On the other hand, data demonstrate a OS benefit of the JAK1/JAK2 inhibitor ruxolitinib …

de (code pays fourni par la source)